Insulin glargine and lixisenatide Subcutaneous and Oracit
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Oracit and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: citric acid / sodium citrate
Brand name: Bicitra, Cytra-2, Liqui-Dual Citra, Oracit, Shohl's Solution, Virtrate-2
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Orajel
- Insulin glargine and lixisenatide Subcutaneous-Orajel Extra Strength
- Insulin glargine and lixisenatide Subcutaneous-Oral Gel
- Insulin glargine and lixisenatide Subcutaneous-Oralair
- Insulin glargine and lixisenatide Subcutaneous-Oralair Adult Sample Kit
- Insulin glargine and lixisenatide Subcutaneous-Oralair Childrens and Adolescents Sample Kit
- Oracit-Insulin glargine, recombinant Subcutaneous
- Oracit-Insulin glulisine
- Oracit-Insulin Glulisine (Cartridges and Pens)
- Oracit-Insulin Glulisine (Vials)
- Oracit-Insulin glulisine Subcutaneous
- Oracit-Insulin human inhaled Inhalation